COVID-19. ?????? ??? ?????
Conditions
Interventions
Intervention 1: Intervention group: Recommended standard care for COVID-19 patients + Trifluoperazine, 2 mg tablet PO (manufactured by Sobhandarou, Iran) q12hr for 21 days. Intervention 2: Control gro
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: ?All of the patients admitted to Razi hospital of Rasht and diagnosed for COVID-19 in April-March 2020 18 years old and more ?Fever (oral temperature more than 37.8) At least one of the following criteria Respiratory rate 24 and more per minute At rest SPO2 fewer than 94 PCR positive Pulmonary involvement in CT or chest X-ray
Exclusion criteria
Exclusion criteria: Those who aren't willing to participate in the study based on personal satisfaction concomitant use of an anti-psychotic drug History of epileptic disorders Parkinson's Disease Dementia Symptomatic hepatic dysfunction Allergic reaction to Phenothiazines History of pheochromocytoma Any major drug-interaction between routine-taken drugs with trifluoperazine Pregnancy and breastfeeding Previous COVID-19 treatment Multi-organ failure evidences Need to mechanical ventilation on entrance to the study eGFR< 50 mL/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to clinical improvment: normalization of body temperature to 37.2 and lower. Timepoint: Daily. Method of measurement: Clinical examination.;Time to clinical improvment: normalization of respiratory rate to 24 and fewer. Timepoint: Daily. Method of measurement: Clinical examination.;Time to clinical improvment: Oxygen saturation of 94% and more. Timepoint: Daily. Method of measurement: Palse oximeter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Need to ventilator. Timepoint: Daily. Method of measurement: Clinical assessment.;Radiologic changes. Timepoint: 21st day or anytime based on clinical team diagnosis. Method of measurement: Chest imaging.;Serious adverse drug reactions. Timepoint: anytime. Method of measurement: clinical evaluation.;Morbidity. Timepoint: anytime. Method of measurement: clinical evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNematollah Ahangar
Rasht University of Medical Sciences
Outcome results
None listed